> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Charleston Reacquires Hydrocodone Pipeline Rights
- URL: https://www.fdaweb.com/charleston-reacquires-hydrocodone-pipeline-rights/
- Published: 2017-08-31T12:00:00.000Z
- Updated: 2026-09-14T22:45:52.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5139518

Charleston Laboratories says it has reacquired all U.S. rights to develop and commercialize its hydrocodone pipeline products from Daiichi Sankyo, ending a three-year collaboration. Charleston [says](http://www.prnewswire.com/news-releases/charleston-laboratories-inc-reacquires-rights-to-novel-investigational-treatment-cl-108-for-acute-pain-and-opioid-induced-nausea-and-vomiting-300512101.html?ref=fdaweb.com) it is centralizing its comprehensive acute pain portfolio and accelerating the process to bring its CL-108 (hydrocodone, acetaminophen, promethazine), an investigational treatment for managing pain severe enough to require an opioid analgesic while preventing or reducing the associated opioid-induced nausea and vomiting when alternative treatments for pain are inadequate, to market. It says it plans to resubmit the CL-108 NDA soon. FDA had issued a complete response letter to Charleston and Daiichi last February, saying the NDA was not approvable.